Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

Abstract Number: 1521 • 2015 ACR/ARHP Annual Meeting
Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Renata Baronaite Hansen¹, Anne Brun Hesselvig², Rolf Magnus Arpi², Eva Kristin Jonassen¹, Gunhild Bukh¹ and Ole Rintek Madsen¹, ¹Department of Rheumatology/C, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Department of Clinical Microbiology, Department of Clinical Microbiology, Copenhagen University Hospital Herlev, Herlev, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) treated with biologic agents are at increased risk of infection. Therefore, screening for urinary tract infection (UTI) with urine…
Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting
Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Matthias H. Thomas¹, Klaus Krüger², Pee Aries³, Martin Bohl-Buehler⁴, Jan Brandt-Juergens⁵, Verena Rickert⁶ and Siegfried Wassenberg⁷, ¹Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, ²Praxiszentrum St. Bonifatius, München, Germany, ³Rheumatologie im Struenseehaus, Hamburg, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Praxis Brandt-Juergens/Karberg, Berlin, Germany, ⁶Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, ⁷Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
Abstract Number: 1677 • 2015 ACR/ARHP Annual Meeting
Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis
Mathijs G.A. Broeren¹, Miranda B. Bennink¹, Onno J. Arntz², Wim van den Berg² and Fons A.J. van de Loo², ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: The current treatment for patients with rheumatoid arthritis (RA) consists of biological drugs, often in combination with methotrexate. However, some patients fail to respond…
Abstract Number: 2581 • 2015 ACR/ARHP Annual Meeting
TNF-Alpha Receptor II Signaling Plays an Important Role in Maintaining the Expression of Forkhead Box P3 in Murine Regulatory T Cells
Wen-Yi Tseng^1,2, Kay McNamee¹, Adam Cribbs³, Anviti Vyas¹ and Richard O. Williams¹, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan, ³Computational Genomics and Training Centre, MRC Functional Genomics Unit, University of Oxford, Oxford, United Kingdom
Background/Purpose: TNF-α is a key regulator of inflammation, which induces signal transduction by binding to two structurally and functionally distinct receptors on target cells: TNF…
Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Femke Lamers-Karnebeek¹, Marjan Ghiti Moghadam², Harald E. Vonkeman³, Janneke Tekstra⁴, Annemarie Schilder⁵, Henk Visser⁶, Peter M. ten Klooster⁷, Eric H. Sasso⁸, David Chernoff⁹, Willem Lems¹⁰, Dirkjan van Schaardenburg¹¹, Robert Landewé¹², Iet Van Albada¹³, T.R.D.J. Radstake¹⁴, Piet van Riel¹⁵, Mart A.F.J. van de Laar¹⁶ and Tim Jansen¹⁷, ¹Rheumatology, Radboudumc, Nijmegen, Netherlands, ²rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, ⁶Rheumatology, Alysis Care Group, Arnhem, Netherlands, ⁷Pcgr, University of Twente, Enschede, Netherlands, ⁸Crescendo Bioscience Inc., South San Francisco, CA, ⁹Crescendo Bioscience, Inc., South San Francisco, CA, ¹⁰Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Department of Rheumatology, Amsterdam, Netherlands, ¹¹Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, ¹²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ¹³Meander MC, Amersfoort, Netherlands, ¹⁴Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…
Abstract Number: 3170 • 2015 ACR/ARHP Annual Meeting
Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Mie Jin Lim¹, Won Park², Seong-Ryul Kwon², Kyong-Hee Jung² and Min Jung Son³, ¹Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Inha University Hospital, Incheon, South Korea
Background/Purpose: We investigated osteoclastogenesis and osteoblastogenesis in peripheral blood before and 6 months after TNF blocker treatment in seropositive RA patients. Methods: Seventeen seropositive…
Abstract Number: 2369 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Susan M. Goodman¹, Indu Menon², Rie Smethurst³, Paul Christos⁴ and Vivian P. Bykerk¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, NY, NY, ³Education - Academic Training, Hospital for Special Surgery, NY, NY, ⁴Healthcare Policy and Research, Weill Cornell Medical College, NY, NY
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Susan M. Goodman¹, Indu Menon², Rie Smethurst³, Paul Christos⁴ and Vivian P. Bykerk¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, NY, NY, ³Education - Academic Training, Hospital for Special Surgery, NY, NY, ⁴Healthcare Policy and Research, Weill Cornell Medical College, NY, NY
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting
Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Alper van Sijl¹, Mamas Mamas², Mark Lunt^3,4, . BSRBR Control Centre Consortium³, Kath Watson⁵, Deborah P. Symmons^3,6 and Kimme L. Hyrich⁷, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…
Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Pauline Raaschou¹, Julia F Simard², Charlotte Asker-Hagelberg³, Johan Askling⁴ and the ARTIS Study group⁵, ¹Karolinska Institutet, Stockholm, Sweden, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden, ⁴Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…
Abstract Number: 484 • 2014 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy
Seung Min Jung¹, Hong Ki Min¹, Jung Hee Koh¹, Jin Young Kang¹, Jennifer Lee¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Hyeok-Jae Ko³, Kyung-Su Park⁴, Ho-Youn Kim¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, St. Mary’s hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea, ⁴Internal Medicine, St. Vincent Hospital, SuWon Gyeonggi-do, South Korea
Background/Purpose: Anti-TNF therapy was known to increase the risk of certain infection. There are only limited data about the reactivation of hepatitis B virus (HBV)…
Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting
Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway
Eun Chung Hong¹, Hemin Jeong², Jiwon Hwang², Eun-Kyung Bae¹, Hyungjin Kim², Joong Kyong Ahn³, Hoon-Suk Cha², Eun-mi Koh⁴ and Jaejoon Lee⁴, ¹Samsung Biomedical Research Institute, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Sungkyunkwan univ. school of medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…
Abstract Number: 1427 • 2013 ACR/ARHP Annual Meeting
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Chung-Ming Hsieh¹, Carolyn Cuff², Edit Tarcsa³ and Margaret Hugunin⁴, ¹Biologics, AbbVie Pharmaceuticals, Worcester, MA, ²Immunology, AbbVie, Inc, Worcester, MA, ³Immunology, AbbVie Bioresearch Center, Worcester, MA, ⁴Molecular and Cellular Pharmacology, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Rheumatoid arthritis (RA) is a serious autoimmune disease that significantly impacts patients’ quality of life. Several approved biologic drugs targeting tumor necrosis factor (TNF)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].